购物车
- 全部删除
- 您的购物车当前为空
Sotrovimab (VIR 7831)为一种人源化IgG1κ泛冠状病毒(sarbecvirus)单克隆抗体,能够中和SARS-CoV-2、SARS-CoV-1以及其他多种冠状病毒。该药物基于S309研发,拥有较长半衰期,在呼吸道黏膜中展现出较高的生物利用度。Sotrovimab有助于免疫介导的病毒清除,预防Covid-19早期发展。
Sotrovimab (VIR 7831)为一种人源化IgG1κ泛冠状病毒(sarbecvirus)单克隆抗体,能够中和SARS-CoV-2、SARS-CoV-1以及其他多种冠状病毒。该药物基于S309研发,拥有较长半衰期,在呼吸道黏膜中展现出较高的生物利用度。Sotrovimab有助于免疫介导的病毒清除,预防Covid-19早期发展。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 期货 |
产品描述 | Sotrovimab (VIR 7831), a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), effectively neutralizes SARS-CoV-2, SARS-CoV-1, and various other sarbecoviruses. Developed from S309, it possesses a prolonged half-life and excellent bioavailability within the respiratory mucosa. Its mechanism potentially facilitates immune-mediated viral elimination, thereby averting the advancement of Covid-19 during the disease's early stages [1][2]. |
CAS No. | 2423014-07-5 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.